Articles Tagged With: pneumonia
-
Interleukin-6 Antagonists in the Treatment of Severe COVID-19 Pneumonia
These two trials had disparate findings with respect to interleukin-6 inhibition, with REMAP-CAP showing a benefit and COVACTA showing none. -
Evaluation and Treatment of Severe Community-Acquired Pneumonia in the ICU
Community-acquired pneumonia is a common cause for hospital admission. This article serves to summarize new updates in the definition, prognosis, and treatment, specifically of bacterial, severe community-acquired pneumonia.
-
Infectious Disease Alert Updates
IL-6 Inhibition and Liver Failure; Can Chopsticks Make You Sick?
-
Mechanical Ventilation for Pneumonia, Acute Respiratory Distress Syndrome, and COVID-19
This article discusses mechanical ventilation for patients with pneumonia, acute respiratory distress syndrome, and COVID-19.
-
Lefamulin: Formulary Considerations
The Food and Drug Administration (FDA) recently approved lefamulin for the treatment of adults with community-acquired bacterial pneumonia (CABP).
-
Antibiotic Therapy to Reduce the Incidence of Ventilator-Associated Pneumonia After Cardiac Arrest
In this prospective, randomized trial, intravenous amoxicillin-clavulanate (dosed three times daily and given for two days) administered to patients admitted with out-of-hospital cardiac arrest due to a shockable rhythm reduced the incidence of early ventilator-associated pneumonia.
-
Empiric Anti-MRSA Therapy in Pneumonia May Not Always Be a Good Idea
In a retrospective cohort study, empiric anti-methicillin-resistant Staphylococcus aureus treatment was not associated with a reduction in mortality in any subgroup of patients studied and appeared to cause harm in many.
-
Antibiotic Therapy to Reduce the Incidence of Ventilator-Associated Pneumonia After Cardiac Arrest
In this prospective, randomized trial, intravenous amoxicillin-clavulanate (dosed three times daily and given for two days) administered to patients admitted with out-of-hospital cardiac arrest due to a shockable rhythm reduced the incidence of early ventilator-associated pneumonia.
-
Empiric Anti-MRSA Therapy in Pneumonia May Not Always Be a Good Idea
In a retrospective cohort study, 88,605 patients in the Veterans Administration system who were hospitalized with pneumonia were examined. Thirty-eight percent received empiric anti-methicillin-resistant Staphylococcus aureus (MRSA) treatment. Empiric anti-MRSA treatment was not associated with a reduction in mortality in any subgroup of patients studied and appeared to cause harm in many patients.
-
Cefiderocol (Fetroja)
Cefiderocol is a novel siderophore cephalosporin with a wide spectrum of activity against difficult-to-treat gram-negative organisms for which there currently are limited treatment options.